Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management

Emerging monoclonal antibody therapies are assuming greater importance in the management of severe and refractory forms of immunity-driven and oncological disorders. However, some have been found to induce adverse ocular events (AOEs) leading to discontinuation of treatment or additional multidiscip...

Descripción completa

Detalles Bibliográficos
Autores principales: Mickevicius, Tomas, Pink, Andrew E., Bhogal, Maninder, O'Brart, David, Robbie, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cornea 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973444/
https://www.ncbi.nlm.nih.gov/pubmed/36525340
http://dx.doi.org/10.1097/ICO.0000000000003162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973444/
https://www.ncbi.nlm.nih.gov/pubmed/36525340
http://dx.doi.org/10.1097/ICO.0000000000003162

Ejemplares similares